Pressmeddelanden, rapporter och bolagsmeddelande för PILA PHARMA AB

PILA PHARMA AB is inviting investors to an online webinar on February 27, 2025, where CEO Gustav H. Gram will discuss the company's 2024 second half-year report and their TRPV1 antagonist for obesity and related disorders. The company, listed on Nasdaq First North Growth Market, is a Swedish biotech firm focusing on developing TRPV1 antagonists as treatments for type 2 diabetes, obesity, and other inflammatory diseases. Their lead compound, XEN-D0501, has shown promise in clinical trials for obesity and type 2 diabetes, and has been granted orphan drug designation for erythromelalgia. PILA PHARMA is also exploring its use for abdominal aorta aneurysm, with preclinical success in reducing aneurysm growth in mice. The company is preparing for further clinical trials to assess safety and efficacy in these conditions.

PILA PHARMA AB has announced the completion of a study by Professor Dick Wågsäter's Research Group at Uppsala University, which showed that their TRPV1 antagonist, XEN-D0501, significantly reduced the growth of Abdominal Aorta Aneurysm (AAA) in mice. This establishes a preclinical proof-of-concept for the drug's potential to reduce chronic inflammation leading to cardiovascular diseases, including aorta dilatation. The study revealed that XEN-D0501 decreased aorta dilatation by over 50% compared to placebo, nearly inhibiting aneurysm development in the model. The results await further validation before publication. PILA PHARMA focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. XEN-D0501 has shown good safety profiles in previous trials and is being prepared for further clinical studies. The company also holds patents for using TRPV1 antagonists in treating obesity and diabetes. PILA PHARMA is based in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market.

PILA PHARMA AB has appointed Hampus Darrell as its new Chief Financial Officer (CFO). Hampus brings extensive experience in accounting and financial management, having worked in various roles at KPMG and E.ON, and as CFO at Setterwalls Advokatbyrå. He holds a Master of Science in Business and Economics from Lund University and became a Swedish Certified Public Accountant in 2005. Hampus will join PILA PHARMA part-time from December 2024, succeeding Elna Lembrér Åström, who is retiring. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. The company owns the development candidate XEN-D0501, which has shown promise in clinical trials. PILA PHARMA is working on projects related to type 2 diabetes, erythromelalgia, and abdominal aorta aneurism. The company also collaborates with Uppsala University to study the effects of XEN-D0501 on abdominal aorta aneurism growth in mice.

PILA PHARMA AB has announced the start of a study in collaboration with Professor Dick Wågsäter's research group at Uppsala University. The study aims to investigate the effects of PILA PHARMA's lead molecule, XEN-D0501, on the growth of Abdominal Aorta Aneurism (AAA) in mice. The hypothesis is that XEN-D0501 may reduce inflammation leading to cardiovascular diseases, potentially preventing AAA's progression. PILA PHARMA will co-sponsor the research, with the Research Group retaining publication rights after patenting. If successful, this study could lead to human trials. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. XEN-D0501 has shown promise in previous trials for diabetes and obesity, and the company is planning further clinical trials to explore its potential benefits.

PILA PHARMA AB, a Swedish biotech company, invites investors to several upcoming Nordic events where CEO Gustav H. Gram will discuss the company's innovative treatment for metabolic disorders. The company focuses on developing TRPV1 antagonists, particularly XEN-D0501, for conditions like type 2 diabetes, obesity, and erythromelalgia. XEN-D0501 has shown promise in clinical trials, improving insulin response and reducing cardiovascular biomarkers. The company plans further trials to assess safety and efficacy. PILA PHARMA also explores treatments for erythromelalgia and abdominal aorta aneurism, collaborating on preclinical studies to investigate XEN-D0501's potential effects. Diabetes and obesity are highlighted as significant global health issues, with obesity linked to increased risk of type 2 diabetes and cardiovascular diseases. The company's shares are traded on Nasdaq First North Growth Market in Sweden.

PILA PHARMA AB (publ) announced that its Chairman of the Board, Dorte X. Gram, and CEO, Gustav H. Gram, have purchased additional shares in the company. Dorte X. Gram, along with Gustav H. Gram, acquired 20,000 shares through their family investment vehicle, Gram Equity Invest AB, at an average price of SEK 4.99. Dorte X. Gram's total holdings now amount to 5,215,086 shares. Separately, Gustav H. Gram privately acquired 11,072 shares on November 15 and 5,914 shares on November 18, at an average price of SEK 4.58, bringing his total holdings to 96,802 shares. Both leaders expressed confidence in the company's potential, particularly in developing TRPV1 antagonists for treating metabolic diseases such as obesity, diabetes, and cardiovascular disease. PILA PHARMA is a Swedish biotech company focusing on developing these antagonists as novel treatments for type 2 diabetes and other inflammatory diseases. The company owns the TRPV1 asset XEN-D0501, which has shown promise in clinical trials. PILA PHARMA is also involved in projects related to erythromelalgia and abdominal aorta aneurism, with ongoing research and development efforts.

PILA PHARMA AB (publ) invites viewers to watch or listen to a broadcast of "Millionærklubben," featuring CEO Gustav H. Gram. He will discuss the company's innovative pill treatment for diabetes, obesity, and other metabolic disorders. The episode is in Danish and will be available on PILA PHARMA's digital platforms. PILA PHARMA is a Swedish biotech firm focused on developing TRPV1 antagonists, particularly XEN-D0501, for treating type 2 diabetes and other conditions. The company has completed two phase 2a clinical trials showing XEN-D0501 is well tolerated and enhances insulin response. Future plans include further trials to assess the safety and efficacy of the drug. PILA PHARMA is also exploring treatments for erythromelalgia and abdominal aorta aneurism. The company collaborates with Uppsala University to study XEN-D0501's effects on aneurism growth in mice.

PILA PHARMA AB has announced the selection of Professor Mark Evans as the principal investigator and Cambridge University Hospital as the main clinical trial site for their study PP-CT03. The decision follows changes to the trial plan due to safety concerns with non-hospital sites. PILA PHARMA will seek scientific advice from the UK MHRA to enhance the study design for their TRPV1 antagonist, XEN-D0501, aimed at treating diabetes and obesity. The company aims to optimize study efficacy and regulatory approval chances. Despite potential delays, they expect to receive scientific feedback in early 2025. PILA PHARMA focuses on developing treatments for type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurism. Their lead molecule, XEN-D0501, has shown promise in previous trials and is being further developed for its potential benefits in metabolic diseases.

PILA PHARMA AB announced a co-sponsorship with Professor Dick Wågsäter's Research Group at Uppsala University to study the effects of their lead molecule, XEN-D0501, on Abdominal Aorta Aneurism (AAA) growth in mice. The research, supported by approximately SEK 150,000, aims to establish a pre-clinical proof-of-concept that XEN-D0501 could potentially prevent the progression of AAA by reducing chronic inflammation. PILA PHARMA will co-sponsor the project and will obtain patent rights in exchange for sponsoring any resulting patents. The study could pave the way for assessing the molecule's effects in humans if successful. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for various conditions, including type 2 diabetes, obesity, erythromelalgia, and AAA. XEN-D0501 has shown promise in previous trials for its safety and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The collaboration with Professor Wågsäter addresses a significant unmet need for AAA treatment, which currently lacks preventive options.

PILA PHARMA AB has revised the operational plan for its upcoming clinical trial, PP-CT03, a phase 2a trial focusing on safety and tolerability in individuals with obesity and type 2 diabetes. Initially set to be conducted at a non-hospital site using digital approaches, concerns about handling safety events have led to the decision to conduct the trial at a hospital site instead. This change is expected to slightly delay the clinical trial application submission but will allow for better management of higher doses and potential safety issues. The trial aims to establish the maximal tolerable dose of XEN-D0501 and assess its efficacy in weight reduction. The company is evaluating the impact on costs and timelines. PILA PHARMA is a Swedish biotech company focusing on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. The company owns several patents and is involved in projects related to diabetes, erythromelalgia, and abdominal aorta aneurism.